Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT05188469

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

COVID-19 Vaccine Clinical Trial

Official title:
A Phase I/IIa (Multi-center, Open-label, Phase I and Multi-center, Open-label, Phase IIa ) Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

Clinical Trial Summary

This is Phase 1 and 2a, Multi-center, Open-label study designed to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo vaccine in Healthy Adult Volunteers

Clinical Trial Description

Subjects will undergo a Screening period beginning up to 14 days prior to enrollment, the vaccination(s) will be administered on Day 0 and Day 21, pre- and post-dose assessment, follow-up visits, and an end of study (EOS) or early termination (ET) visit (as applicable). Subjects will be enrolled prior to vaccination on Day 0, to one (1) of two (2) or three (3) treatment groups. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05188469
Study type Interventional
Source EyeGene Inc.
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date March 22, 2022
Completion date August 1, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT05049226 - Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine Phase 2
Recruiting NCT05998824 - COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease N/A
Recruiting NCT05097053 - A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19 Phase 4
Active, not recruiting NCT05463419 - A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose. Phase 2/Phase 3
Active, not recruiting NCT05293223 - Phase IIB Study of Recombinant Novel Coronavirus Vaccine Phase 2
Completed NCT04691947 - Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC Phase 1
Completed NCT05288231 - Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand
Completed NCT04546841 - Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults Phase 1
Recruiting NCT04963790 - Enabling Family Physicians to Reduce Vaccine Hesitancy and Increase Covid-19 Vaccine Uptake N/A
Completed NCT05216601 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19 Phase 1
Completed NCT04566276 - ChulaCov19 Vaccine in Healthy Adults Phase 1/Phase 2
Completed NCT04915820 - Iron and COVID-19 Vaccine Response N/A
Completed NCT05268679 - Covid-19 Vaccine Response in Heart Transplant Recipients
Completed NCT04898946 - Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
Recruiting NCT05869968 - SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
Active, not recruiting NCT05197712 - Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease Phase 1
Recruiting NCT05553743 - Researchers at UC San Diego Are Learning About the Benefits of Human Milk and How it Influences Infant and Child Health
Completed NCT04764422 - Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand Phase 1/Phase 2
Recruiting NCT04838080 - Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo Phase 1
Recruiting NCT05822219 - Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases N/A